 | |  | |  | |  | |  | |  | |  | |  |
| IJCEM Copyright © 2008-All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711 |
Int J Clin Exp Med 2012;5(4):363-366
Case Report
68Ga-DotaTATE PET-CT followed by Peptide Receptor
Radiotherapy in combination with capecitabine in
two patients with Merkel Cell Carcinoma
Matthias C Schmidt, Klara Uhrhan, Birgid Markiefka, Laura Hasselbring, Max Schlaak, Birgit Cremer,
Sabine Kunze, Richard P Baum, Markus Dietlein
Department of Nuclear Medicine, University Hospital of Cologne, Germany; Institute of Pathology, University Hospital
of Cologne, Germany; Ear, Nose and Throat Department, University Hospital of Cologne, Germany; Department
of Dermatology, University Hospital of Cologne, Germany; Department I for Internal Medicine, University Hospital of
Cologne, Germany; Department of Radiation Oncology, University Hospital of Cologne, Germany; Department of
Nuclear Medicine / Center for PET, Bad Berka, Germany.
Received August 14, 2012; accepted August 25, 2012; Epub September 28, 2012; Published September 15, 2011
Abstract: Herein, we report about two Caucasian patients with the histopathological diagnosis of Merkel cell carcinoma
suffering from extensive lymph node metastases. The extent of the disease was diagnosed by Ga-68-DotaTATEPET-
CT. Both patients had rapid disease progression, one of them despite a three months course of sunitinib followed
by four chemotherapy cycles of cisplatin and etoposide. Both patients were sent for peptide receptor radiotherapy
with 90Y-DotaTATE or 177Lu-DotaTATE in combination with capecitabine. Additional external beam radiotherapy of the
cervical and inguinal lymph nodes was given to the patient with progressive disease despite chemotherapy. Temporary
partial response in both patients was achieved. Despite extensive therapeutic efforts, fatal outcome could not be
prevented 10 and 14 months after first clinical symptoms. (IJCEM1208002)
Keywords: Merkel cell carcinoma (MCC), PET-CT, 68Ga-DotaTATE, 90Y-DotaTATE, 177Lu-DotaTATE, Peptide Receptor
Radiotherapy (PRRT), Theranostic
Address all correspondence to:
Matthias C Schmidt, MD
Department of Nuclear Medicine, University Hospital
of Cologne, Kerpener Str. 62
D – 50937 Köln (Cologne), Germany.
Phone: + 49-221-478-4052;
Email: Matthias.Schmidt@uni-koeln.de
Case Report
68Ga-DotaTATE PET-CT followed by Peptide Receptor
Radiotherapy in combination with capecitabine in
two patients with Merkel Cell Carcinoma
Matthias C Schmidt, Klara Uhrhan, Birgid Markiefka, Laura Hasselbring, Max Schlaak, Birgit Cremer,
Sabine Kunze, Richard P Baum, Markus Dietlein
Department of Nuclear Medicine, University Hospital of Cologne, Germany; Institute of Pathology, University Hospital
of Cologne, Germany; Ear, Nose and Throat Department, University Hospital of Cologne, Germany; Department
of Dermatology, University Hospital of Cologne, Germany; Department I for Internal Medicine, University Hospital of
Cologne, Germany; Department of Radiation Oncology, University Hospital of Cologne, Germany; Department of
Nuclear Medicine / Center for PET, Bad Berka, Germany.
Received August 14, 2012; accepted August 25, 2012; Epub September 28, 2012; Published September 15, 2011
Abstract: Herein, we report about two Caucasian patients with the histopathological diagnosis of Merkel cell carcinoma
suffering from extensive lymph node metastases. The extent of the disease was diagnosed by Ga-68-DotaTATEPET-
CT. Both patients had rapid disease progression, one of them despite a three months course of sunitinib followed
by four chemotherapy cycles of cisplatin and etoposide. Both patients were sent for peptide receptor radiotherapy
with 90Y-DotaTATE or 177Lu-DotaTATE in combination with capecitabine. Additional external beam radiotherapy of the
cervical and inguinal lymph nodes was given to the patient with progressive disease despite chemotherapy. Temporary
partial response in both patients was achieved. Despite extensive therapeutic efforts, fatal outcome could not be
prevented 10 and 14 months after first clinical symptoms. (IJCEM1208002)
Keywords: Merkel cell carcinoma (MCC), PET-CT, 68Ga-DotaTATE, 90Y-DotaTATE, 177Lu-DotaTATE, Peptide Receptor
Radiotherapy (PRRT), Theranostic
Address all correspondence to:
Matthias C Schmidt, MD
Department of Nuclear Medicine, University Hospital
of Cologne, Kerpener Str. 62
D – 50937 Köln (Cologne), Germany.
Phone: + 49-221-478-4052;
Email: Matthias.Schmidt@uni-koeln.de
